MA55362A - Formulations stabilisées contenant des anticorps anti-il-33 - Google Patents

Formulations stabilisées contenant des anticorps anti-il-33

Info

Publication number
MA55362A
MA55362A MA055362A MA55362A MA55362A MA 55362 A MA55362 A MA 55362A MA 055362 A MA055362 A MA 055362A MA 55362 A MA55362 A MA 55362A MA 55362 A MA55362 A MA 55362A
Authority
MA
Morocco
Prior art keywords
antibodies
formulations containing
containing anti
stabilized formulations
stabilized
Prior art date
Application number
MA055362A
Other languages
English (en)
Inventor
Qingyan Hu
Dingjiang Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA55362A publication Critical patent/MA55362A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/20Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321Means for protection against accidental injuries by used needles
    • A61M5/3243Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MA055362A 2019-03-21 2020-03-20 Formulations stabilisées contenant des anticorps anti-il-33 MA55362A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962821661P 2019-03-21 2019-03-21

Publications (1)

Publication Number Publication Date
MA55362A true MA55362A (fr) 2022-01-26

Family

ID=70228884

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055362A MA55362A (fr) 2019-03-21 2020-03-20 Formulations stabilisées contenant des anticorps anti-il-33

Country Status (19)

Country Link
US (2) US11596690B2 (fr)
EP (1) EP3941522A1 (fr)
JP (2) JP7695887B2 (fr)
KR (1) KR20210141592A (fr)
CN (3) CN113573733B (fr)
AU (1) AU2020241882A1 (fr)
BR (1) BR112021018727A2 (fr)
CA (1) CA3133995A1 (fr)
CL (1) CL2021002440A1 (fr)
CO (1) CO2021011648A2 (fr)
EA (1) EA202192568A1 (fr)
IL (2) IL286024B2 (fr)
MA (1) MA55362A (fr)
MX (1) MX2021011137A (fr)
PH (1) PH12021552092A1 (fr)
SA (1) SA521430229B1 (fr)
SG (1) SG11202109822XA (fr)
TW (2) TW202519263A (fr)
WO (1) WO2020191270A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
BR112022022620A2 (pt) * 2020-05-11 2022-12-20 Medimmune Ltd Formulações de anticorpos anti-il-33
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023077685A1 (fr) * 2021-11-04 2023-05-11 江苏荃信生物医药股份有限公司 Procédé de préparation d'une solution concentrée comprenant un anticorps monoclonal contre l'interleukine-33 humaine et préparation liquide
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0600351D0 (en) * 2006-01-10 2006-02-15 Weston Terence E Safe hypodermic needle
CA2685124A1 (fr) 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin Produits pour modifier l'activite d'il-33 et procedes correspondants
EP2069784A4 (fr) 2007-05-18 2009-11-18 Medimmune Llc Il-33 dans une maladie inflammatoire
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
EP2768858B1 (fr) * 2011-10-18 2018-08-01 Emory University Anticorps antigrippaux
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
HRP20181227T1 (hr) * 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
KR102687412B1 (ko) * 2015-10-06 2024-07-24 리제너론 파아마슈티컬스, 인크. 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019010895A (es) * 2017-03-16 2019-11-05 Lg Chemical Ltd Formulacion liquida de anticuerpo anti-tnf alfa.
EP3966227A1 (fr) * 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
CN112851814B (zh) * 2020-03-17 2023-07-07 西安宇繁生物科技有限责任公司 一种靶向bcma的全人源单链抗体及其制备方法与应用
US20240101667A1 (en) * 2020-12-03 2024-03-28 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法

Also Published As

Publication number Publication date
CO2021011648A2 (es) 2021-09-30
AU2020241882A1 (en) 2021-10-14
CN113573733B (zh) 2024-12-31
CN119700966A (zh) 2025-03-28
BR112021018727A2 (pt) 2022-02-15
WO2020191270A1 (fr) 2020-09-24
TW202519263A (zh) 2025-05-16
CL2021002440A1 (es) 2022-04-22
CN119700965A (zh) 2025-03-28
TW202102260A (zh) 2021-01-16
US20230346929A1 (en) 2023-11-02
IL317899A (en) 2025-02-01
IL286024B2 (en) 2025-05-01
US20200297845A1 (en) 2020-09-24
SG11202109822XA (en) 2021-10-28
CA3133995A1 (fr) 2020-09-24
EA202192568A1 (ru) 2021-12-03
JP7695887B2 (ja) 2025-06-19
TWI861073B (zh) 2024-11-11
US11596690B2 (en) 2023-03-07
EP3941522A1 (fr) 2022-01-26
IL286024B1 (en) 2025-01-01
PH12021552092A1 (en) 2022-05-30
MX2021011137A (es) 2021-10-22
CN113573733A (zh) 2021-10-29
JP2025131756A (ja) 2025-09-09
IL286024A (en) 2021-10-31
SA521430229B1 (ar) 2024-01-23
JP2022526292A (ja) 2022-05-24
KR20210141592A (ko) 2021-11-23

Similar Documents

Publication Publication Date Title
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
MA49043A (fr) Formulation stable d'anticorps
EP3449940A4 (fr) Préparation contenant un anticorps
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3581651A4 (fr) Anticorps anti-gprc5d et molécule le contenant
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP3825404A4 (fr) Car contenant un anticorps monocaténaire anti-gpc3
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
MA51903A (fr) Formulations d'anticorps b7-h4
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA54052A (fr) Formulation d'anticorps
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA54139A (fr) Formulation d'anticorps
EP3995582A4 (fr) Anticorps anti-epha4
EP3831851A4 (fr) Anticorps anti-btla
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés
MA53466A (fr) Formulation stable d'anticorps anti-osmr